Thursday May 17, 2007
|
|
|
|
|
|
|
|
| 7:00 - 8:00 |
Continental Breakfast & Registration |
|
|
|
|
|
|
| 8:00 - 8:30 |
Welcome: The Global Neurotech Industry 2007 |
|
|
|
|
|
|
|
|
Zack Lynch |
|
|
|
Executive Director, Neurotechnology Industry Organization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 8:30 - 9:15 |
Investing in Neurotech Panel |
|
|
|
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries? |
|
|
|
|
|
|
Ellen Baron
|
|
|
Partner, Oxford Bioscience Partners
|
|
|
|
|
|
Nicola Campell |
|
|
General Partner, Sofinnova Ventures |
|
|
|
|
|
Matthew Perry
|
|
|
Portfolio Manager, Biotechnology Value Fund
|
|
|
|
|
|
|
|
|
Roger Quy
|
|
|
General Partner, Technology Partners
|
|
|
|
|
|
Moderator: Casey Crawford Lynch
|
|
|
Managing Partner, NeuroInsights
|
|
|
|
|
|
|
|
| 9:15 - 10:15 |
Emerging Drugs and Devices for Epilepsy and Seizure Disorders |
|
|
|
Antiepileptics are one of the largest revenue categories in neurotech. This is due in part to off-label prescribing for neuropathic pain and bipolar disorder. What are the latest advances in drugs and devices for the treatment of epilepsy and neuropathic pain? Neurostimulation devices are making inroads into refractory epilepsy. What are the most promising approaches and how are they different from pharmaceutical treatments?
|
|
|
|
|
|
|
Frank Fischer |
|
|
CEO, NeuroPace |
|
|
|
|
|
Leo Liu
|
|
|
President and Chief Scientific Officer, Cambria Biosciences
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rich Masterson |
|
|
Vice President & General Manager,Valeant Pharmaceuticals |
|
|
|
|
|
|
|
|
Session Chair: Warren Lammert |
|
|
Founder, Epilepsy Therapy Development Project |
|
|
|
|
|
|
|
| 10:15 - 10:45 |
Networking and Refreshment Break |
|
|
|
|
|
|
|
|
| 10:45 - 12:00 |
Advances in Neuropsychiatry: Schizophrenia, Depression, and Anxiety |
|
|
|
Schizophrenia, anxiety, depression, and other neuropsychiatric illnesses represent a large portion of the neuropharmaceutical market. How is polypharmacy, the use of multiple drugs to treat an illness, playing a role in drug development strategies? What are the most promising next generation treatments?
|
|
|
|
|
|
Jeff Bacha |
|
|
Executive VP and COO, Clera |
|
|
|
|
|
Mark Bausinger |
|
|
CFO, Neuronetics
|
|
|
Barry Brand |
|
|
CEO, CeNeRx Biopharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mark Varney |
|
|
COO and CSO, Cortex Pharmaceuticals |
|
|
|
|
|
Session Chair: Harry Tracy |
|
|
Publisher, NeuroInvestment
|
|
|
|
|
|
|
|
| 12:00 - 1:30 |
Luncheon Keynote
|
|
|
Dr. Michael Huerta
Associate Director, National Institute of Mental Health
"Accelerating the Decade of Translation"
|
|
|
|
|
|
|
|
|
| 1:30 - 2:30 |
Stroke: Prevention, Protection, and Recovery |
|
|
|
Stroke is generally considered one of the highest risk disease categories for development due to a heterogeneous patient population, short therapeutic window, and poorly defined therapeutic endpoints. A clear unmet need in prevention, protection, and recovery continues to drive innovation and investment into diverse approaches to new drugs and devices for stroke patients. We’ll hear from 4 companies with novel approaches to treatment and recovery. |
|
|
|
|
|
Alan Levy |
|
|
President and CEO, Northstar Neuroscience |
|
|
|
|
|
Alan Moore |
|
|
President and CEO, Stem Cell Therapeutics |
|
|
|
|
|
Peter Rule |
|
|
Chairman and CEO, Ekos
|
|
| |
|
|
|
|
|
|
Andrew Weiss |
|
|
CEO, CoAxia Inc. |
|
|
|
|
|
|
|
|
|
|
|
Session Chair: Frank Eeckman |
|
|
Neurotech Insights, Centient Biotech |
|
|
|
|
| 2:30 - 3:15 |
Regulatory and Reimbursement Issues Panel |
|
|
|
Working with the FDA for approval and CMS for reimbursement is critical to the success of any neurotech venture. The interviewer will lead an insider panel in a discussion of issues facing the industry and tactics for improving development times and successfully navigating the path to approval and reimbursement.
|
|
|
Edward Allera
|
|
|
Buchanan, Ingersoll & Rooney PC
|
|
|
|
|
|
Shawn Lunney |
|
|
Vice President Market Development, Cyberonics |
|
|
|
|
|
Cynthia Rask |
|
|
Former FDA Director, Division of Clinical Evaluation and Toxicology |
|
|
|
|
|
Moderator: Elizabeth Smith
|
|
|
Partner, Nixon Peabody
|
|
|
|
|
| 3:15 - 3:45 |
Networking and Refreshment Break |
|
|
|
|
|
| 3:45 - 4:45 |
Growth of Specialty Neuropharma |
|
|
|
Focused companies that in-license later stage product have become highly popular with investors. These companies have the potential to leverage targeted salesforces while virtually eliminating R&D expenses. What are the long term plans and prospects for specialty neuropharma companies?
|
|
|
|
|
|
J. Donald deBethizy |
|
|
President and CEO, Targacept |
|
|
|
|
|
Vincent Simmon |
|
|
President and CEO, Xytis Pharmaceuticals |
|
| |
|
|
| |
Tim Tasker |
|
| |
Executive Vice President Clinical Development, Evotec |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tom Woiwode |
|
|
VP Business Development, Synosia |
|
|
|
|
|
Session Chair: Charles Duncan |
|
|
Managing Director, JMP Securities |
|
|
|
|
| 4:45 - 5:30 |
Brain Fitness Through Software and Neurofeedback
|
|
|
Spurred by the discovery of neuroplasticity, the aging baby boomer population and demand for safe treatments for childhood ADHD, software companies, large and small, are venturing into the realm of therapy and cognitive fitness. Venture investors are drawn by the potential of the large markets, lack of FDA involvement, and scalability of the software model. What challenges are companies facing? What efficacy parameters are required for success?
|
|
|
Rolf Hallencreutz |
|
|
Chairman of the Board, Cogmed
|
|
|
|
|
|
John Hollister |
|
|
CEO, EEG Spectrum
|
|
|
Jeff Zimman
|
|
|
CEO, Posit
|
|
|
Session Chair: Alvaro Fernandez
|
|
|
CEO and Co-Founder, SharpBrains
|
|
|
|
|
|
|
|
|
|
|
| 5:30 - 6:30 |
Networking and Wine Tasting Reception |
|
|
|
|
|
Sponsored by Staglin Family Vineyards and Nasdaq
|
|
|
|
|
|
|
